Contributing Member of the Healthcare Councils

GLG News by this Author

Federal Govt. Should be the cost

August 8, 2008

Analysis of:UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com

1. Kidney cancer drugs have the potential to extend progression-free survival by five to six months, but at a cost of $40,000 to $70,000 per patient per year.  2. The cost per quality adjusted life year (QALY) gained of these treatments is between $57,000 and $180,000 per patient - based on drugmaker data - but at $142,000 to $340,000 per patient, according to NICE’s independent data. 3.  So who will bear such cost?  is open question to whole world

FDA will ask for more data

August 7, 2008

Analysis of:AstraZeneca and Bristol-Myers Squibb Submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the Treatment of Type 2 Diabetes | www.astrazeneca.com

Saxagliptin is being studied in clinical trials as a once-daily therapy to determine its efficacy and safety. Saxagliptin was specifically designed to be a selective, reversible inhibitor of the DPP-4 enzyme, with dual routes of clearance. Phase III data for saxagliptin have previously been presented in combination with metformin, the most commonly prescribed oral anti-diabetic, as well as when used as monotherapy in treatment-naïve individuals. Additional Phase III data for saxagliptin, including when added to a sulfonylurea, a thiazolidinedione and as initial combination therapy with metformin, are planned for disclosure later this year.

HIV drugs can not be used as prevention

August 6, 2008

Analysis of:Researchers Look to Pill, Taken Daily, to Avert H.I.V. | www.nytimes.com

1.PrEP involves a prescription drug, so it’s likely that initial programs will be clinic-based. PrEP delivery would also require periodic HIV testing. 2. In contrast to male circumcision—or hopefully one day, a vaccine—PrEP would require that people take a drug on an ongoing basis (daily or intermittently). 3. Interest in PrEP could bring more individuals into the health clinic, where they would have access to HIV testing and other services, regardless of whether they chose to use PrEP. 4. It will affect immune system in long run basis.

Sepsis biomarker

July 31, 2008

Analysis of:SIRS-Lab Pre-Announces Biomarker Based Sepsis Test | www.medcompare.com

1.Reliable biomarkers for the early observation of the inflammation status of sepsis are urgently needed. 2. SIQNATURE has major potential to improve the treatment of severe sepsis by the early identification of patients at risk.

Relationship between Angiotensin receptor blocker and Alzheime's disease

July 29, 2008

Analysis of:Blood pressure drugs may protect against Alzheimer's | www.washingtonpost.com

 This article is important because it  opened a new  avenue to do more research to find  relationship between Relationship between Angiotensin receptor blocker and Alzheime's disease.

APOSENSE® [18F]-ML-10- A novel Apoptosis Imaging Agent

July 28, 2008

Analysis of:APOSENSE® [18F]-ML-10 For Molecular Imaging Of Apoptosis To Proceed To Phase I/II Trials | www.medicalnewstoday.com

This  is  very good news  that FDA  approved the letter for clinical trial of APOSENSE® [18F]-ML-10:

drug discovery driven by patient population

July 22, 2008

Analysis of:Glaxo Seeks Guidance From Health Systems | online.wsj.com

Drug discovery driven by patient population, revenue outcome and government willingness to  buy the product

multi target design ligands

July 21, 2008

Analysis of:Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease | www.fiercebiotech.com

 multi target design ligand

Previous Page : 1221 to 28 of 28